English High Court denies Jazz units’ jurisdictional challenge
04-05-2022
Jazz Pharma accused of pay-for-delay deals over Xyrem
14-10-2021
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
Michael Vi / Shutterstock.com
Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem (sodium oxybate).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Xyrem, Jazz Pharmaceuticals, Avadel, big pharma
